Evidence map›Paper›PMID 36567408›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2023

COVID19 vaccine in myasthenia gravis patients: safety and possible predictors of disease exacerbation.

Assunta Trinchillo, Marcello Esposito, Francesco Habetswallner, Francesco Tuccillo, Bernardo Maria De Martino

Open access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Safety of SARS-CoV-2 vaccines in patients with myasthenia gravis: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Article
  4. COVID-19 vaccination in myasthenia gravis: safe, but predictors of disease exacerbation yet to be determined.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Assunta TrinchilloDepartment of Neurosciences, Reproductive Sciences and Odontostomatology, Federico II" University, Via S. Pansini, 5, 80131, Naples, Italy. assuntatrinchillo94@gmail.com.ORCID 0000-0002-9413-3394
Marcello EspositoClinical Neurophysiology Unit, Cardarelli Hospital, Naples, Italy.
Francesco HabetswallnerClinical Neurophysiology Unit, Cardarelli Hospital, Naples, Italy.
Francesco TuccilloClinical Neurophysiology Unit, Cardarelli Hospital, Naples, Italy.
Bernardo Maria De MartinoClinical Neurophysiology Unit, Cardarelli Hospital, Naples, Italy.
Fatebenefratelli Hospital · ITFederico II University Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19COVID-19 VaccinesMyasthenia GravisDisease ProgressionHumansCOVID-19 Vaccines

Identifiers

PMID36567408
PMCPMC9790762
OpenAlexW4313201652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.